Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

An antibody to Streptococcus pneumoniae capsular polysaccharide enhances quorum sensing


ABSTRACT: The primary mechanism by which pneumococcal capsular polysaccharide-based vaccines are believed to mediate protection is by induction of serotype-specific opsonic antibodies that facilitate bacterial killing by phagocytes (opsonophagocytosis). However, antibodies that are protective against experimental pneumococcal pneumonia in mice but do not promote opsonophagocytic killing in vitro have also been identified 1-3. Such non-opsonic antibodies are associated with bacterial clearance in vivo, but the mechanism by which this occurs is unknown. In this letter, we demonstrate that a protective, non-opsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody (MAb) enhances quorum sensing, which results in competence induction and fratricide of serotype 3 pneumococcus. Gene expression profile analysis revealed that the MAb together with the pneumococcal autoinducer, competence stimulating peptide 2 (CSP2), augments differential expression of competence (com) related bacteriocin-like peptide (blp) genes that are known to be involved in pneumococcal fratricide. Taken together, these findings reveal a previously unsuspected mechanism of antibody action, namely, enhancement of quorum sensing and bacterial fratricide. Given that this activity does not require phagocytes, antibodies that function accordingly may hold promise as adjuncts to current vaccines or as desired products of next generation pneumococcal vaccines. 6 samples

ORGANISM(S): Streptococcus pneumoniae

SUBMITTER: Masahide Yano 

PROVIDER: E-GEOD-27258 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Antibodies to Streptococcus pneumoniae capsular polysaccharide enhance pneumococcal quorum sensing.

Yano Masahide M   Gohil Shruti S   Coleman J Robert JR   Manix Catherine C   Pirofski Liise-anne LA  

mBio 20111101 5


<h4>Unlabelled</h4>The use of pneumococcal capsular polysaccharide (PPS)-based vaccines has resulted in a substantial reduction in invasive pneumococcal disease. However, much remains to be learned about vaccine-mediated immunity, as seven-valent PPS-protein conjugate vaccine use in children has been associated with nonvaccine serotype replacement and 23-valent vaccine use in adults has not prevented pneumococcal pneumonia. In this report, we demonstrate that certain PPS-specific monoclonal anti  ...[more]

Similar Datasets

2011-03-01 | GSE27258 | GEO
2013-12-31 | E-GEOD-45865 | biostudies-arrayexpress
2013-12-31 | GSE45865 | GEO
2010-05-15 | E-GEOD-9670 | biostudies-arrayexpress
2014-11-24 | GSE58329 | GEO
2023-11-08 | GSE247276 | GEO
2023-11-08 | GSE247277 | GEO
2008-12-01 | GSE9670 | GEO
2008-06-16 | E-GEOD-8527 | biostudies-arrayexpress
2018-01-22 | PXD005178 | Pride